GnRH is named as an intervention in 2 current clinical trials in our UK, USA, China, Germany, France, Spain, Netherlands, Belgium, Sweden, Poland, Czechia, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan, Israel and Japan registers. 1 is recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is Aragon Pharmaceuticals, Inc (1). The most-studied condition is Prostatic Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA)
NCT07340827 · ClinicalTrials.gov ↗ · Infertility
|
Phase 3 | Recruiting | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Japan |
|
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
NCT02531516 · ClinicalTrials.gov ↗ · Prostatic Neoplasms
|
Phase 3 | Active, closed | Aragon Pharmaceuticals, Inc | UK, USA, China, Germany, France, Spain, Netherlands, Belgium, Sweden, Poland, Czechia, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Aragon Pharmaceuticals, Inc | 1 |
| Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our UK, USA, China, Germany, France, Spain, Netherlands, Belgium, Sweden, Poland, Czechia, Turkey, Canada, Brazil, Mexico, South Korea, Taiwan, Israel and Japan registers name GnRH as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Japan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Aragon Pharmaceuticals, Inc (1) and Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how GnRH works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how GnRH works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists GnRH (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.